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Stenotrophomonas ssp. has a wide environmental distribution and is also found as an opportunistic pathogen, causing nosocomial
or community-acquired infections. One species, S. maltophilia, presents multidrug resistance and has been associated with serious
infections in pediatric and immunocompromised patients. Therefore, it is relevant to conduct resistance profile and phylogenetic
studies in clinical isolates for identifying infection origins and isolates with augmented pathogenic potential. Here, multilocus
sequence typing was performed for phylogenetic analysis of nosocomial isolates of Stenotrophomonas spp. and, environmental and
clinical strains of S. maltophilia. Biochemical and multidrug resistance profiles of nosocomial and clinical strains were determined.
The inferred phylogenetic profile showed high clonal variability, what correlates with the adaptability process of Stenotrophomonas
to different habitats. Two clinical isolates subgroups of S. maltophilia sharing high phylogenetic homogeneity presented intergroup
recombination, thus indicating the high permittivity to horizontal gene transfer, a mechanism involved in the acquisition of
antibiotic resistance and expression of virulence factors. For most of the clinical strains, phylogenetic inference was made using
only partial ppsA gene sequence. Therefore, the sequencing of just one specific fragment of this gene would allow, in many cases,
determining whether the infection with S. maltophilia was nosocomial or community-acquired.
1. Introduction
The genus Stenotrophomonas is genetically and phenotyp-
ically heterogeneous [1, 2], presently encompassing twelve
recognized species validated in the List of Prokaryotic
Names with Standing inNomenclature (http://www.bacterio.
cict.fr/s/stenotrophomonas.html).
S. maltophilia, the genus type species, besides its biotech-
nological importance (nitrogen fixing, stimulation of plant
growth), has gained clinical importance in the last two
decades, being the only specie of the genus Stenotrophomonas
found in the environment and also as an opportunistic
human pathogen [1, 3, 4]. S. maltophilia occurs in any
aquatic/humid environment and is capable of colonizing
and proliferating in abiotic surfaces, such as Teflon, glass,
and plastics, and it has been isolated in niches as diverse
as catheters, dialysis machine tubing, and drinking water
reservoirs [4], causing nosocomial as well as community-
acquired infections [4–7].
S. maltophilia can cause serious bloodstream and res-
piratory infections in immunocompromised patients, with
reports on crude mortality rates between 18% and 69%
(reviewed by Paez and Costa [8]). S. maltophilia infections
have great relevance in pediatric hospitals, being associated
to high morbimortality rates (crude mortality rates around
40%) in Intensive Care Unit (ICU): hospitalized and/or
immunocompromised patients [9, 10]. Surveys fromdifferent
geographic regions report an increasing rate of S. maltophilia
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infections in the last decade, probably associated with an
escalation of invasive procedures, the spread of naturally
carbapenen-resistant S. maltophilia,and the empirical use of
broad spectrum antibiotics [3, 6, 10–12]. Furthermore, S.
maltophilia is not exclusively a nosocomial pathogen, since
it has been associated with community-acquired infections,
mainly affecting patients with some kind of comorbidity [5, 7]
and mostly related to water supply contamination [4]. In
a recent survey of S. maltophilia bloodstream infections in
Taiwan between 2008 and 2011 (153 cases), Chang et al. [7]
found that 38.6%were community-onset (48.5% community-
acquired and 52.8% healthcare-associated).
S. maltophilia has high-level intrinsic resistance to many
unrelated antibiotics [4, 6]. Besides multidrug-efflux pumps
and low outer membrane permeability, this bacterium can
also acquire antibiotic resistance by horizontal transfer of
resistance genes located on plasmids, transposons, and inte-
grons [3, 4, 13–15]. The remarkable capacity of S. maltophilia
for acquiring genetic factors of resistance to antibiotics and
biocides shows the importance of conducting resistance
profile and phylogenetic studies in clinical isolates, aiming
to identify the origins of horizontal genetic transmission
(environmental, nosocomial), and isolates with augmented
pathogenic potential [4, 16].
Multilocus sequencing typing (MLST) has proven to be
a reliable mean for inter- and intraspecies delineation of
Stenotrophomonas spp. and a highly portable standard for
strain characterization [2, 16]. Moreover, MLST provides
an adequate window of discrimination for distinguishing
among clusters of closely related isolates (clonal complexes)
and, therefore, for unraveling horizontally transferred genetic
information, because it modifies the composition inside
clonal groups [16–19]. Here we used MLST and phylogenetic
analysis, as well as biochemical and multidrug resistance
profiles, for characterizing nosocomial isolates and clini-
cal strains of Stenotrophomonas spp. and for identifying
community- and hospital-acquired origin of nosocomial
isolates.
2. Materials and Methods
2.1. Stenotrophomonas spp. Nosocomial Isolates and Strains.
Twenty-nine nosocomial isolates obtained from Hospital
Israelita Albert Einstein (HIAE), Sa˜o Paulo, SP, Brazil; and
thirteen clinical strains; five environmental strains; and five
type strains (one clinical and four environmental) from dif-
ferent collections, in total 52 bacterial strains (Table 1), were
selected for phylogenetic and phenotypic analyses for deter-
mining their phylogenetic profiles and association with bio-
chemical and multidrug resistance characteristics. Fourteen
of the HIAE nosocomial isolates were collected from patients
hospitalized in the Intensive Care Unit (ICU). The clinical
and environmental strains were obtained from the Belgian
Co-ordinated Collections ofMicro-organisms/Laboratorium
voor Microbiologie of Universiteit Gent (BCCM/LMG,
Gent, Belgium, http://bccm.belspo.be/index.php). The clini-
cal strains were collected between 1976 and 1995 having dif-
ferent geographical origins. One of the five Stenotrophomonas
type strains was obtained from theGermanCultureDeutsche
Sammlung von und Mikroorganismen Zellkulturen GmbH
(DSMZ Braunschweig, Germany) and the remaining four
came from the BCCM/LMG culture collection.
Bacterial strains were preserved in Trypticase Soy Broth
(TSB, Difco Laboratories, Detroit, Michigan) with glycerol
(10% v/v) at −80∘C. Nosocomial isolates were grown in TSB
and, subsequently, these strains were cultivated on Trypticase
Soy Agar (TSA, Difco Laboratories, Detroit, Michigan) to
check for any eventual contamination. Belonging to the genus
Stenotrophomonas was confirmed by sequencing of a 500 bp
fragment of the 16S rRNA gene.
2.2. Biochemical and Drug Resistance Tests. Biochemical
phenotyping of nosocomial isolates and bacterial strains was
attained by using the API 20NE kit (BioMe´rieux, Marcy-
I’Etoile, France). Nitrogen-fixing capability—a common
characteristic of environmental Stenotrophomonas strains—
was determined for all the nosocomial and clinical strains
here studied by means of the acetylene reduction assay, using
the nitrogen fixing strain Azospirillum brasilense Sp7T as
positive control [20].
The antibiotic resistance profiles of Stenotrophomonas
nosocomial isolates and strains were determined by using
susceptibility test discs [21, 22]. Bacteria were grown on
Mueller-Hinton agar in the presence of the following antibi-
otic discs (Cefar Diagno´stica Ltda., Sa˜o Paulo, Brazil): amox-
icillin/clavulanic acid, 30 𝜇g; imipenem, 10 𝜇g; meropenem,
10 𝜇g; ceftazidime, 30 𝜇g; cefotaxime, 30 𝜇g; aztreonam,
30 𝜇g; ciprofloxacin, 5 𝜇g, levofloxacin, 5 𝜇g; chlorampheni-
col, 30 𝜇g, trimethoprim-sulfamethoxazole, 25𝜇g; tetracy-
cline, 30 𝜇g; and tobramycin, 10 𝜇g.The results were evaluated
according to CLSI [21, 22].
2.3. Genomic DNA Extraction. Total genomic DNA of bacte-
rial strains was extracted by using theWizard Genomic DNA
Purification Kit (cat. no. A1120, Promega Corporation,Madi-
son, WI), according to the manufacturer’s instructions. DNA
quality and concentration were determined through 1.0%
agarose gel electrophoresis using the Invitrogen Low Mass
ladder (cat. no. 10068013, Invitrogen Corporation, Carlsbad,
CA) and ethidium bromide staining and visualization under
UV light.
2.4. Phylogenetic Analysis by Multilocus Sequence Typing
(MLST). Seven constitutive genes were chosen for phylo-
genetic analysis. Six of these genes— atpD, gapA, guaA,
ppsA, nuoD, and recA—were firstly employed for inferring
the population structure of the genus Stenotrophomonas by
Kaiser et al. [16]. We also included the constitutive gene rpoA
already used by our group [23].
Amplification conditions for gapA, guaA, ppsA, recA, and
rpoA were 1X Taq DNA polymerase buffer, 1.5mM MgCl
2
,
2 U of Taq DNA polymerase (cat. no. 10342020 Invitrogen
Corporation, Carlsbad, CA), 25mM of dNTPs, 10mM of for-
ward and reverse primers [16, 23], andwater to adjust the final
reaction volume to 50 𝜇L. The amount of DNA per reaction
ranged from 20 to 40 ng depending on the size of the gene
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Table 1: Nosocomial isolates, clinical and environmental strains, and type strains of Stenotrophomonas spp..
Strains Source
Nosocomial strains
HIAE 1911, HIAE 1990, HIAE 1998, HIAE 2336,
HIAE 2425, HIAE 2737, HIAE 2947, HIAE 3182,
HIAE 3338, HIAE 3576, HIAE 3730, HIAE 3808,
HIAE 4003, HIAE 4249, HIAE 4471, HIAE 4500,
HIAE 4600, HIAE 4638, HIAE 4800, HIAE 4920,
HIAE 4948, HIAE 5124, HIAE 5399U
Tracheal secretion
HIAE 2229, HIAE 2505 Drain secretion
HIAE 5180 Leg ulcer
HIAE 3369 Human blood culture
HIAE 5188 Eye secretion
HIAE 3673 Brochoalveolar lavage
Clinical strains
LMG 957, LMG 10851, LMG 10857∗, LMG 10874∗, LMG 11114 Human blood culture
LMG 10853∗ Tracheal secretion
LMG 10877∗ Patient suffering from sinusitis, pus
LMG 10989 Bile
LMG 10991∗ Leg, pus
LMG 10992 Expectoration
LMG 11002 Mamilla
LMG 11004 Urine
LMG 22072 Cerebrospinal fluid
Environmental strains
LMG 11089, LMG 11090 Cichorium intybus rhizosphere
LMG 11105, LMG 11108 Triticum roots
LMG 6608 rhizosphere
Type strains
LMG 958 S. maltophilia Cortical necrosis
LMG 22073 S. acidaminiphila Mud
LMG 22074 S. nitritireducens∗ Laboratory scale filter
LMG 25348 S. pavanii Sugar cane
DSMZ 17805 S. koreensis∗ Compost (straw + manure)
∗Genomic sequences deposited in the GenBank were utilized in addition to sequences obtained in our laboratory for the genomic analysis by MLST. UStrains
collected in the ICU of Hospital Israelita Albert Einstein (HIAE).
fragment to be amplified. The PCR reaction was performed
for 40 cycles at the following temperatures: denaturation of
DNA at 95∘C/6min, annealing at 62∘C/15 sec, and extension
at 72∘C/1min and 15 sec. A final extension was performed
at 72∘C/7min. In order to amplify the sequences of atpD
and nuoD [16], the annealing temperatures were decreased
to 60∘C and 48∘C, respectively. The amplified products were
purified with GFX PCR DNA and Gel Band Purification Kit
(cat. no. 27-9602-01, GE Healthcare, Buckinghamshire, UK),
following the manufacturer’s instructions.
The sequencing reactions were performed using the
Big Dye Terminator v3.1 Cycle Sequencing Kit (catalog no.
4337455, Applied Biosystems, Austin, Texas) and precipitated
with the Big Dye XTerminator Purification Kit (catalog no.
4376486, Applied Biosystems, Austin, TX) following the
manufacturer’s instructions. The cycling temperatures were
95∘C/20 sec for denaturing, 50–55∘C/15 sec for annealing, and
60∘C/1min for elongation. This cycle was repeated 30 times.
The sequences were read in the ABI 3500 Genetic Analyzer
(Applied Biosystems, Forest City, California).
Sequence quality was analyzed and consensus sequences
were identified by using the software Chromas Pro version
1.5 (Technelysium Pty Ltd, http://www.technelysium.com.
au/chromas.html). After obtaining the consensus sequences
for each bacterial strain, these sequences were exported in
FASTA format for phylogenetic inference using the software
MEGA 5 [24]. The phylogenetic trees were constructed by
the neighbor-joining (NJ) method [25, 26], based on the p-
distance [27, 28].
The GenBank (http://www.ncbi.nlm.nih.gov/genbank/)
accession numbers for gene nucleotide sequences with
200 bp or more are atpD, KC209168-KC209214; recA,
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KC209215-KC209254; ppsA, KC209255-KC209300; gapA,
KC209301-KC209345; nuoD, KC209346-KC209384; and
guaA, KC209385-KC209424. These data were publicly
released by GenBank on February 17, 2013.
Analysis of nucleotide sequence diversity was performed
for the nosocomial isolates, clinical strains, and type strains
using the software DNAsp [29] (DNA Sequence Polymor-
phism version 4.10) for atpD, gapA, guaA, nuoD, ppsA, recA,
and rpoA genes. The parameter Pi (nucleotide diversity)
corresponds to the average number of nucleotide differences
per site between two sequences [30, 31] and its sampling
variance [30].
3. Results
3.1. Biochemical and Drug Resistance Tests. All bacterial
strains, with the exception of the four environmental type
strains, five well-characterized environmental strains from
LMG collection (see Section 2), three nosocomial isolates,
and eight clinical strains were tested biochemically and
identified as belonging to the genus Stenotrophomonas, what
was confirmed for all clinical and nosocomial isolates by
16S rRNA gene sequencing. Theresults showed extensive
biochemical similarity between these isolates (see Table 2).
Moreover, all nosocomial isolates and clinical strains were
found to be unable to reduce acetylene, revealing their
incapacity for fixing nitrogen.
The 42 bacterial strains tested for drug resistance
(Table 3) showed sensitivity to levofloxacin. The sensitivity
to other antimicrobials was slightly or considerably lower:
chloramphenicol (97.6%), trimethoprim-sulfamethoxazole
(90.5%), ciprofloxacin (88.1%), ceftazidime (76.2%), tetra-
cycline (71.4%), and tobramycin (71.4%). The isolates were
resistant to imipenem (97.6%), cefotaxime (95.2%), aztre-
onam (85.7%), amoxicillin/clavulanic acid (85.7% each), and
meropenem (81%). Interestingly, the majority of clinical
isolates studied here show resistance to various beta-lactams
(AMC, IPM,MER, CAZ, CTX, and ATM), a characteristic of
clinical isolates of S. maltophilia [32, 33].
3.2. MLST Phylogenetic Analysis. In order to conduct phylo-
genetic studies using MLST data, fragments of seven consti-
tutive genes were amplified and sequenced for 45 strains and
for 7 strains were obtained fromGenBank [2, 16] as indicated
in Table 1. After sequence alignment, fragments sized 136
to 401 nucleotides for the atpD, gapA, guaA, nuoD, ppsA,
recA and rpoA genes were used for nucleotide diversity and
phylogenetic analyses. The gene with the highest number of
polymorphic sites (87 sites) was guaA, followed by recA (66
sites), and the genes rpoA, ppsAand gapAhad the higher rates
of nucleotide diversity (Table 4).
Concatenated sequences were firstly obtained using frag-
ment sequences of atpD, gapA, guaA, ppsA, nuoD, recA,
and rpoA from 47 bacterial samples. These concatenated
sequences were utilized to construct a neighbor-joining
tree (based on p-distance). The phylogram (Figure 1) shows
the division of these 47 strains in two groups: group A
contains three type strains of environmental species of the
genus Stenotrophomonas and groupB includes all nosocomial
strains and type strains of S. maltophilia and S. pavanii.
Interestingly, group B is divided into three major sub-
groups (bootstrap > 70): B.I and B.II sharing high phyloge-
netic homogeneity and subgroup B.III, more heterogeneous,
encompassing three clusters of strains (bootstrap > 99).
Phylograms were also constructed using one-gene fragments
(ppsA or recA genes).The ppsAphylogram (Figure 2) shows a
tree topology very similar to phylogram based on seven genes
concatenated as depicted in Figure 1. On the other hand, the
recA phylogram (Figure 3) shows a shuffling between the
B.III clusters and B.I subgroup, thus favoring the hypothesis
of intersubgroup recombination. It is worth to note that
groups B.I and B.III comprise isolates and strains with higher
resistance to antibiotics.
3.3. Phylogenetic Analysis Including Environmental Strains
of S. Maltophilia. A phylogram for analyzing the genetic
similarity between clinical and environmental isolates of the
genus Stenotrophomonas (all strains of Table 1) was built
using the concatenated fragment sequences of the genes
atpD, gapA, guaA, ppsA, nuoD, and recA (Figure 4). In
this phylogram, it is possible to observe the formation of
two groups of strains with higher phylogenetic proximity:
group A contains only three environmental type strains
of Stenotrophomonas and Group B contains all the other
clinical and environmental strains plus the type strains of
S. maltophilia and S. pavanii. Considering the phylogenetic
proximities, group B can be divided in four subgroups (B.I
to B.IV). B.I includes the five environmental strains of S.
maltophilia and four nosocomial strains. B.II contains the
type-strain of S. maltophilia and 12 nosocomial strains. B.III
encompasses seven nosocomial isolates. B.IV contains the
type-strain of S. pavanii and 14 nosocomial strains. The
subgroup B.IV is subdivided into three small clusters: B.IV.1
and B.IV.2 encompass only nosocomial strains and B.IV.3
encompasses nosocomial strains and the type-strain of S.
pavanii.
It is important to note that the subgroups and clusters
B.II, B.III, B.IV.1, B.IV.2, and B.IV.3 have high phylogenetic
similarity (bootstrap values between 99 and 100). Moreover,
most of the strains in the groups B.II, B.III, B.IV.1, and B.IV.2
exhibit some intragroup metabolic differences, whereas the
samples grouped into B.IV.1 show the same biochemical
profile (Table 2). This phenotypic divergence between strains
and isolates belonging to the same phylogenetic group
indicates multiplicity of origin, as will be discussed later.
Finally, the phylogram depicted in Figure 4 also shows that
the majority of nosocomial isolates and clinical strains are
phylogenetically distinct from environmental strains of S.
maltophilia.
4. Discussion
This study adopted a phylogenetic approach—based on anal-
ysis of nucleotide sequences of fragments of specific genes
by constitutive multilocus sequencing typing (MLST)—to
investigate the clonal variability of nosocomial isolates and
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Figure 1: Neighbor-joining phylogram of 47 Stenotrophomonas spp. clinical strains based on 7 concatenated genes. Neighbor-joining
phylogram (1000 bootstrap replications, p-distance model) derived from concatenation of atpD, guaA, gapA, nuoD, ppsA, recA, and rpoA
gene sequences. Phylogenetic groups and subgroups are indicated by A, B, B.I, B.II, B.III, B.III.1, B.III.2, and B.III.3. The numbers at branch
nodes represent bootstrap values ≥ 50.
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Figure 2: Neighbor-joining phylogram of 47 Stenotrophomonas spp. clinical strains based on ppsA gene fragment. Neighbor-joining
phylogram (1000 bootstrap replications, p-distance model) for the gene ppsA. Phylogenetic groups and subgroups are indicated by A, B,
B.I, B.II, B.III, B.III.1, B.III.2, and B.III.3 similarly to the concatenated tree depicted in Figure 1. The numbers at branch nodes represent the
bootstrap values.
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Figure 3: Neighbor-joining phylogram of 47 Stenotrophomonas spp. clinical strains based on recA gene fragment. Neighbor-joining
phylogram (1000 bootstrap replications, p-distance model) for the gene recA. The phylogenetic groups and subgroups are indicated by A,
B, B.I, B.II, B.III, B.III.1, B.III.2, and B.III.3 similarly to the concatenated tree depicted in Figure 1. Note the shuffling between B.III clusters.
The numbers at branch nodes represent bootstrap values.
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Figure 4: Neighbor-joining phylogram of 52 Stenotrophomonas spp. clinical and environmental strains based on 6 concatenated genes.
Neighbor-joining phylogram (1000 bootstrap replications, p-distance model) derived from concatenation of atpD, guaA, gapA, nuoD, ppsA,
and recAgene sequences. Phylogenetic groups and subgroups are indicated byA, B, B.I, B.II, B.III, B.IV, B.IV.1, B.IV.2, and B.IV.3.The numbers
at branch nodes represent bootstrap values ≥ 50.
BioMed Research International 9
Table 2: API 20 NE biochemical profile of Stenotrophomonas spp. phylogenetically close subgroups shown in Figure 1 or Figure 4.
Phylogenetic groups Strains Biochemical profile
Figure 1 Figure 4 NO3 ADH URE PNPG
B.III.3 B.IV.3
HIAE 1998 − − − +
HIAE 2229 − − − +
HIAE 2425 − − − +
LMG 11114 − − − +
B.III.2 B.IV.2
HIAE 3673 + + − +
LMG 11002 − − + −
HIAE 3730 − − − −
HIAE 4003 + − − +
B.III.1 B.IV.1
HIAE 5124 − + − +
HIAE 3369 + + − +
LMG 957 + − − +
LMG 10853 − − + +
HIAE 2336 − − − +
B.II B.III
HIAE 3338 − − − +
HIAE 3576 − − − −
HIAE 4600 + − − +
HIAE 4500 − − − +
HIAE 4800 − − − +
HIAE 3808 − − − +
HIAE 5399 − − − +
B.I B.II
HIAE 4920 − − − −
HIAE 4249 − − − −
HIAE 1911 − − − +
HIAE 4948 − − − +
HIAE 3182 + − − +
HIAE 1990 − − − −
LMG 958 + − − +
HIAE 5188 + − − +
LMG 10992 + − + −
HIAE 4638 + − − +
HIAE 2505 − − − −
HAIE 2737 − − − −
NO3: Potassium nitrate, ADH: L-arginine, URE: urea, and PNPG: 4-nitrophenyl 𝛽-D-galactopyranoside.
All strains were negative for the following: TRP: L-tryptophane, GLU: D-glucose (fermentation), ARA: L-arabinose, MAN: D-mannitol, GNT: potassium
gluconate, CAP: capric acid, ADI: adipic acid, PAC: phenylacetic acid, and OX: oxidase and positive for the following: ESC: esculin, GEL: gelatin, GLU: D-
glucose (assimilation), MNE: D-mannose, NAG: N-acetyl-glucosamine, MAL: D-maltose, MLT: malic acid, and CIT: trisodium citrate.
Strains LMG 25348, HIAE 2947, and HIAE 4471 were not tested.
clinical strains of the genus Stenotrophomonas, which were
also characterized biochemically and for their antibiotic
resistance profile. This study allowed us to correlate the
phylogenetic and phenotypic profiles with a multiclonal
origin, reflecting the process of adaptability of bacteria of the
genus Stenotrophomonas to different habitats.
A common phenotypic trait of all clinical strains and
nosocomial isolates of Stenotrophomonas spp. studied in
this work is their incapacity for nitrogen fixation. Biological
nitrogen fixation is typical of environmental S. maltophilia
(as well as of other Stenotrophomonas species) and depends
on the nitrogenase structural gene nifH [21, 34, 35]. The
expression of nif genes is controlled by nitrogen availability
or the energetic status of the bacterial cell [36]. Therefore,
one is tempted to hypothesize that the loss of the nifH gene
cluster [37] could be an energy-saving adaptive event favoring
the transition from free-living to opportunistic pathogen
phenotype.
Phylogenetic analysis by MLST clearly showed that the
nosocomial isolates and clinical strains of Stenotrophomonas
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Table 3: Antibiotic resistance profile of Stenotrophomonas spp. strains. Phylogenetic subgroups are indicated (Figure 1 or Figure 4).
Phylogenetic groups Strains Drugs tested: inhibition halo diameter in mm/resistance level MR
Figure 1 Figure 4 AMC IPM MER CAZ CTX ATM CIP LVX CHL SXT TET TOB
B.III.3 B.IV.3
HIAE 1998 0/R 0/R 0/R 17/I 0/R 0/R 17/I 20/S 22/S 23/S 19/S 0/R +
HIAE 2229 0/R 0/R 0/R 22/S 11/R 0/R 22/S 30/S 26/S 29/S 22/S 15/S +
HIAE 2425 0/R 0/R 0/R 25/S 12/R 0/R 29/S 33/S 29/S 25/S 18/I 15/S +
LMG 11114 0/R 0/R 0/R 25/S 15/I 0/R 28/S 33/S 29/S 21/S 21/S 0/R +
B.III.2 B.IV.2
HIAE 3673 0/R 0/R 0/R 22/S 9/R 0/R 23/S 30/S 20/S 26/S 20/S 23/S +
LMG 11002 30/S 0/R 28/S 36/S 18/I 0/R 32/S 28/S 34/S 34/S 20/S 28/S +
HIAE 3730 0/R 0/R 0/R 16/I 0/R 0/R 27/S 33/S 30/S 27/S 17/I 15/S +
HIAE 4003 0/R 0/R 0/R 27/S 15/I 0/R 29/S 33/S 28/S 31/S 25/S 25/S +
B.III.1 B.IV.1
HIAE 5124 10/R 8/R 13/R 28/S 16/I 0/R 36/S 36/S 26/S 30/S 24/S 26/S +
HIAE 3369 12/R 0/R 13/R 30/S 19/I 0/R 31/S 35/S 28/S 24/S 16/I 23/S +
LMG 957 11/R 0/R 10/R 32/S 20/S 0/R 31/S 28/S 21/S 34/S 17/I 21/S +
LMG 10853 18/S 0/R 20/S 40/S 21/I 0/R 30/S 33/S 32/S 27/S 26/S 22/S +
HIAE 2336 10/R 0/R 0/R 16/I 0/R 0/R 15/R 21/S 22/S 20/S 0/R 25/S +
B.II B.III
HIAE 3338 11/R 0/R 12/R 28/S 12/R 22/S 27/S 32/S 29/S 28/S 20/S 24/S +
HIAE 3576 10/R 0/R 22/S 25/S 17/I 16/I 28/S 29/S 26/S 17/S 17/I 23/S +
HIAE 4600 12/R 0/R 11/R 26/S 0/R 23/S 30/S 33/S 32/S 24/S 21/S 22/S +
HIAE 4500 0/R 0/R 0/R 17/I 0/R 0/R 27/S 33/S 27/S 29/S 25/S 20/S +
HIAE 4800 0/R 0/R 0/R 31/S 0/R 0/R 28/S 31/S 21/S 27/S 28/S 20/S +
HIAE 3808 9/R 0/R 0/R 20/S 0/R 0/R 28/S 29/S 28/S 24/S 22/S 18/S +
HIAE 5399 0/R 0/R 0/R 17/I 0/R 0/R 29/S 30/S 36/S 25/S 23/S 22/S +
B.I B.II
LMG 22072 0/R 0/R 0/R 0/R 10/R 0/R 23/S 26/S 23/S 25/S 19/S 16/S +
HIAE 5180 0/R 0/R 0/R 31/S 12/R 0/R 23/S 33/S 34/S 31/S 33/S 12/R +
HIAE 4920 11/R 0/R 0/R 0/R 0/R 0/R 0/R 31/S 31/S 21/S 19/S 25/S +
HIAE 4249 10/R 0/R 0/R 21/S 0/R 0/R 9/R 17/S 29/S 0/R 13/R 0/R +
HIAE 1911 8/R 0/R 0/R 20/S 0/R 0/R 22/S 26/S 30/S 17/S 10/R 0/R +
HIAE 4948 0/R 0/R 0/R 31/S 0/R 0/R 28/S 31/S 21/S 27/S 22/S 0/R +
HIAE 3182 0/R 0/R 0/R 18/S 10/R 0/R 20/I 17/S 23/S 24/S 19/S 0/R +
HIAE 1990 0/R 0/R 0/R 10/R 0/R 0/R 26/S 25/S 27/S 0/R 13/R 12/R +
LMG 958 S. maltophilia 24/S 0/R 23/S 29/S 15/I 23/S 36/S 36/S 34/S 26/S 27/S 18/S −∗
HIAE 5188 18/S 0/R 0/R 28/S 10/R 0/R 38/S 40/S 30/S 38/S 26/S 18/S +
LMG 10992 0/R 0/R 0/R 22/S 13/R 0/R 27/S 31/S 31/S 26/S 23/S 15/S +
HIAE 4638 0/R 0/R 0/R 21/S 0/R 0/R 23/S 27/S 23/S 21/S 21/S 23/S +
HIAE 2505 0/R 0/R 0/R 10/R 15/I 0/R 36/S 36/S 25/S 26/S 24/S 0/R +
HIAE 2737 12/R 0/R 0/R 16/I 0/R 0/R 29/S 32/S 34/S 27/S 18/I 0/R +
B B.I
LMG 11004 0/R 0/R 0/R 24/S 10/R 0/R 30/S 34/S 0/R 0/R 22/S 25/S +
LMG 10991 10/R 0/R 32/S 28/S 10/R 32/S 38/S 32/S 30/S 38/S 24/S 34/S +
LMG 10851 0/R 0/R 0/R 26/S 13/R 0/R 34/S 40/S 36/S 28/S 16/I 38/S +
LMG 10877 0/R 0/R 0/R 20/S 0/R 0/R 26/S 29/S 28/S 27/S 22/S 25/S +
LMG 10989 16/I 8/R 24/S 26/S 12/R 24/S 32/S 40/S 30/S 28/S 30/S 8/R +
LMG 10857 0/R 0/R 0/R 29/S 0/R 0/R 24/S 28/S 25/S 26/S 13/R 0/R +
A A LMG 22073 S. acidaminiphila 30/S 13/R 42/S 29/S 16/I 42/S 35/S 37/S 33/S 17/S 31/S 28/S −
∗
DSMZ 17805 S. koreensis 39/S 37/S 41/S 31/S 40/S 0/R 28/S 29/S 32/S 0/R 32/S 25/S −
MR: Multidrug resistance. Amoxicillin/clavulanic acid (AMC); imipenem (IPM); meropenem (MER); ceftazidime (CAZ); cefotaxime (CTX); aztreonam
(ATM); ciprofloxacin (CIP); levofloxacin (LVX); chloramphenicol (CHL); trimethoprim-sulfamethoxazole (SXT); tetracycline (TET); tobramycin (TOB).The
drug tests were not performed for HIAE 2947, HIAE 4471, LMG 10874, LMG 22074, LMG 25348, S. pavanii, and S. nitritireducens strains.
Resistance levels: bold font: resistant; italic font: intermediate; normal font: sensible.
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Table 4: Nucleotide diversity of the Stenotrophomonas spp. analyzed in this study.
Gene Fragment size (bp) Polymorphic sites Mutations Nucleotide diversity (Pi)
synonymous nonsynonymous
atpD (3) 303 24 2 22 0.02013
gapA (1) 314 55 48 7 0.03592
guaA (3) 401 87 8 79 0.02889
nuoD (1) 213 32 28 4 0.02742
ppsA (1) 257 56 46 10 0.03763
recA (1) 254 67 58 9 0.03749
rpoA (1) 136 29 17 12 0.03904
Numbers between parentheses indicate the transcription initiation base position.
spp. here studied have multiclonal origin and that the noso-
comial isolates are grouped separately from environmental
strains of the genus Stenotrophomonas (excepting S. pavanii).
The pattern here observed is that of clonal complexes: groups
are closely related, but not identical, to probable origin in a
relatively recent common ancestor [16–18].
Thephylogenetic groups and subgroups (see Figures 1 and
4) show high values (higher than 80) of bootstrap, indicating
that amount of genetic variability here analyzed was adequate
for defining five clonal groups (in Figure 1: subgroups B.I;
B.II; B.III.1, 2, and 3 or in Figure 4: subgroups B.II and
B.IV. 1, 2, and 3) among the clinical samples included in
this study. Importantly, the 29 clinical samples isolated from
HIAE patients of which 14 were collected from ICU patients
(see Table 1) between August 2005 and July 2006 and 13
strains of clinical LMG, isolated at different times (between
1976 and 1995) and with distinct geographical origins, are
positioned inside the subgroups B.I and B.III or B.II and B.IV
identified in the phylograms shown in Figure 1 or Figure 4,
respectively. Altogether, these data are consistent with a
scenario of community-origin infections.
The multiclonal origin of clinical strains and nosocomial
clinical isolates studied here is consistentwith the characteris-
tics of emerging and opportunistic pathogen described for S.
maltophilia [4]. Moreover, this characterization is supported
by detection of multidrug resistance in all these isolates
and strains, what is a distinctive property of opportunistic
pathogens of environmental origin [1, 4]. In the case of this
study, it is worth to note that the majority of clinical isolates
showed resistance to beta-lactams, which is typical of clinical
isolates of S. maltophilia [11, 32, 33].
It is also interesting to note that some strains and clinical
isolates with large phylogenetic proximity, with bootstrap
values between 99 and 100 (see Figure 4 and Table 2), which
could be considered as belonging to the same clonal group, do
not share full identity in themetabolic profile, which indicates
the community origin of these isolates and adaptive plasticity
of its genome.
Comparative analysis of the phylograms based on ppsA
(Figure 2) and recA (Figure 3) genes indicates the occurrence
of intergroup genetic recombination involving subgroup
B.III: there is clear separation between subgroups B.I and
B.III in the phylogram generated from ppsA, but there is an
overlapping of B.I subgroup and part of samples of B.III.2 and
B.III.3 subgroups in the phylogram generated from recA.This
result suggests the occurrence of a mechanism of horizontal
transfer of genetic material that may occur by the insertion of
phage, plasmids, pathogenic islands, or action of transposons
[18, 38]. Moreover, it is well established that S. maltophilia
can acquire genes involved in the resistance to antimicrobial
agents and antibiotics from other environmental bacteria
through horizontal gene transfer [4, 14].
Horizontal gene transfer events can modify the composi-
tion of clonal groups as evidenced by studies ofMLST [16–19].
This is precisely the case of the isolates that integrate the B.I
and B.III subgroups. This finding by MLST analysis indicates
that the genome of subgroup B.III would be permissive to
gain new factors of virulence and of resistance to antimicro-
bial agents. In fact, strains of the subgroups B.I and B.III are
among themostmultiresistant to antibiotics in this study (see
Table 3).
The constitutive genes guaA, gapA, ppsA, and rpoA
showed the highest nucleotide variability among the seven
genes selected for phylogenetic analysis by MLST (Table 4).
Using data from sequencing of specific fragments of these
genes, four phylograms were generated and the phylogram
generated from ppsA gene fragment sequence showed the
discrimination of clonal groups closest to the concatenated
phylogram shown in Figure 1.This result has practical interest
since it indicates that the sequencing of a fragment of 257 bp
of the ppsA gene can serve to discriminate between clonal
groups of isolates of the genus Stenotrophomonas.This simpli-
fied scheme can be employed in a clinical laboratory to check
whether the infection with S. maltophilia was nosocomial or
community-acquired.
5. Conclusions
The results of this work show that phylogenetic analysis by
MLST is an important tool for the investigation of the genus
Stenotrophomonas as an emerging pathogen. Such analysis is
appropriate to identify the nosocomial or community origin
of infections, serving to detect outbreaks and allowing a study
of the population structure of the pathogen that is important
for molecular epidemiology [16–18]. Moreover, studies using
MLST are useful to investigate the origin of community
infections by S. maltophilia and identify intermediate hosts,
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an area that remains unclear [4]. As emphasized by Maiden
[17], MLST provides universal and rapid means for the iden-
tification of clonal complexes corresponding to hyperinvasive
strains while they are spreading globally.
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